Obligations, precautions and pending issues in regulatory development for radiopharmaceuticals in Brazil by Gamboa, Maryelle Moreira Lima et al.
*Correspondence: M. Gamboa. PPG BioSaude, Universidade Luterana do 
Brasil. Av. Farroupilha, 8001 – Prédio 22 – 5º andar, 92425-900 – Canoas – RS, 
Brasil. E-mail: maryellelg@hotmail.com
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 50, n. 2, apr./jun., 2014
http://dx.doi.org/10.1590/S1984-82502014000200007
Obligations, precautions and pending issues in regulatory 
development for radiopharmaceuticals in Brazil
Maryelle Moreira Lima Gamboa1,*, Heveline Rayane Moura Roesch1,  
Vanessa Pinheiro Amaral Lemos1, Bruna Oliveira Rocha2, Ralph Santos-Oliveira3
1PPG BioSaude, Universidade Luterana do Brasil, Canoas, RS, Brazil, 2Faculty of Biology, Universidade Luterana do Brasil, 
Canoas, RS, Brazil, 3Institute of Radiopharmacy Research, Universidade Estadual da Zona Oeste, Rio de Janeiro, RJ, Brazil
Radiopharmaceuticals are compounds that have a radionuclide and may be gamma-radiation emitter (γ) 
or positrons emitter (β+), linked to a molecule with specific diagnostic and therapeutic purposes. The 
progress in the use of radiopharmaceuticals has culminated to a sector in common with other types of 
drugs: regulation and surveillance. From 2006 on, production, marketing and use of these drugs were 
open to the Brazilian market granting much more freedom due to the Constitutional Amendment 49, 
resulting from the previous Constitutional Amendment 199/03 which removes the Union monopoly for 
this kind of manipulation and granted this production to other nuclear medicine. From this date on, the 
amount of this type of sold product have been greatly increased, and the nucleus of surveillance and 
regulation in Brazil have also advanced in the legislative processes, creating documents that are now 
more focused on radiopharmaceuticals in the national territory (Resolutions No. 63 and No. 64). In 
international overview, there is too much to be done in regulatory terms in Brazil, such as adding mainly 
issues of drugs surveillance to pharmacovigilance practice in radiopharmaceuticals drugs.
Uniterms: Radiopharmaceuticals/regulation. Radiopharmaceuticals/ surveillance.Radiopharmaceuticals/
pharmacovigilance.Pharmacovigilance/practice in radiopharmaceuticals drugs. Brazilian legislation/
radiopharmaceuticals control.
Radiofármacos são compostos que possuem um radionucleotídeo, podendo ser emissor de radiação 
gama (γ) ou emissor de pósitrons (β+), ligado a uma molécula específica com finalidade diagnóstica 
e terapêutica. O avanço no uso dos radiofármacos tem culminado a um setor em comum com outros 
tipos de medicamentos: a regulamentação e fiscalização. Após 2006, a produção, a comercialização e a 
utilização destes medicamentos foram abertas ao mercado interno brasileiro com maior liberdade, pois 
a Emenda Constitucional 49, vinda da Emenda Constitucional 199/03, que retira da União o monopólio 
deste tipo de manipulação, ofereceu a outros centros de medicina nuclear a oportunidade desta produção. 
A partir desta data, a quantidade comercializada deste tipo de medicamento aumentou absurdamente 
e os núcleos de vigilância e regulamentação do Brasil avançaram também nos processos legislativos, 
criando os documentos mais voltados a Radiofármacos existentes no território nacional, as Resoluções 
n° 63 e n° 64. Em visão internacional, há muito ainda a ser feito em termos regulatórios no Brasil 
somando principalmente os assuntos vigilantes dos medicamentos como a prática de Farmacovigilância 
em Radiofármacos.
Unitermos: Radiofármacos/regulamentação. Radiofármacos/fiscalização. Radiofármacos/
farmacovigilância. Farmacovigilância/prática em radiofármacos. Legislação brasileira/controle de 
radiofármacos.
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INTRODUCTION
The Nuclear Medicine is the specialty of medicine 
that uses marked radionuclides – radiopharmaceuticals – 
with therapeutic and diagnostic purposes. It is a procedure 
that allows anatomical, morphological, physiological and 
functional evaluations of organs and tissues.
Radiopharmaceutical agent is any medicinal 
product which, by its pharmaceutical form, quantity and 
quality of radiation emitted can be used in the diagnosis 
and treatment of illnesses of living beings, regardless its 
route of administration (Araújo, 2001). The first use of 
radiopharmaceuticals in humans occurred in 1927, when 
Blumgart and Yens (1926) measured the human blood 
circulation after injection of a saline solution exposed to 
Radon. Later, studies as Hertz Robert, Evans (1938) on the 
function of the thyroid gland with the use of iodine-131 
marked the beginning of the systemic use. 
The radiopharmaceuticals comprise the radionuclide 
generators, the sets of reactive lyophilized to mark 
with Technetium-99 m or Kits and the precursors of 
radiopharmaceuticals. The radionuclide generator is a 
system of production of radiopharmaceuticals where uses 
a radionuclide of long half-life that fades away in another 
radionuclide which elutes (or obtained by methods of 
extraction) for the preparation of radiopharmaceutical
The kits for the preparation of radiopharmaceuticals 
may be lyophilized compounds non-radioactive to be 
reconstituted and/or combined with radionuclides. As for 
the precursors of radiopharmaceuticals, these can be any 
radionuclide produced by radio-labeling of a substance, 
before administration (International Pharmacopoeia, 2004).
The most common radiopharmaceuticals used in 
diagnosis are in their majority the marked with Technetium-
99m (80% of all procedures in Nuclear Medicine) and 
positron emitters, in particular the Fluoride-18, that are 
being used in PET-CT technology (Positron Emission 
Tomography - Computed Tomography). The revolutionary 
system PET-CT unites the diagnostic resources of Nuclear 
Medicine (PET) and Radiology (CT), acting through an 
overlap of metabolic and anatomical images, generating 
images whole body capable of revealing early malignant 
lesions (Robilotta, 2006).
In therapeutic use radioisotopes are used to emit 
beta particles (or alpha), these particles release high power 
energy to reach tissues/cells and cause cell death. The main 
beta emitters used are Iodine-131, Lutetium Isotope 177, 
Itrium-90 and samarium-153.
In Nuclear Medicine the radiopharmaceuticals 
for use in diagnosis and therapy are generally produced 
artificially in particle accelerators or reactors, being also 
accessible through generators of radioisotopes.
These generators allow the use of radionuclide half-
life time (T1/2) short, through the decay of a radionuclide 
with T1/2 long, the latter being produced in reactors or 
ciclotrons. There is also the radionuclides which decays 
by emission of β- particles which are produced in reactor 
by fission of 235U (Uranium235) or by neutron capture 
reactions (n,γ or n,p) in a sample of appropriate target.
On the other hand, the radionuclides which decay by 
electronic capture or emission of β+ particles are produced 
in cyclotrons, where the particles of high energy interact 
with stable nuclei of certain targets, giving rise to products 
handicapped in protons. In this process, the particles that 
interact with the target samples may be protons, deuterons, 
α-particles or 3He (Oliveira et al, 2006).
The progress in the area of obtaining images through 
the use of radiopharmaceuticals demanded a more specific 
Brazilian regulation and also more properly regarding the 
parameters of safety, quality and efficacy.
Currently, Brazilian law provides two Resolutions, 
RDC 63 and 64/2009, published exclusively for 
radiopharmaceuticals (Brasil, 2009a,b).
Thus, the objective of this review article is to describe 
the normative aspects involving radiopharmaceuticals 
with emphasis in Resolutions no. 63 and 64, 2009, and 
prepare a brief evolution of global regulation of this 
therapeutical class.
PHARMACOVIGILANCE
The Pharmacovigilance is a required field of 
importance facing the health and should be performed by 
every holder of record of medicine.
The activities include the detection, evaluation 
and prevention of adverse reactions or problems from 
medications (Brazil, 2009c).
In 1989 it was recommended to the National System 
of Health Surveillance to establish an efficient system 
of Pharmacovigilance track Resolution of the National 
Council of Health, and then, actions of pharmacovigilance 
actions were included as an aid to promote rational use of 
medicines (Brazil 1998).
However, only in 2003 the Unit of Pharmacovigilance 
disclosed information pertinent to the leaflet of 
radiopharmaceuticals and the paramount importance of 
informational reports for the renewal of medicines. After 
the designated Management Pharmacovigilance, in 2007, 
there were Resolutions to standardize and assist this whole 
process, which today, is indispensable to any holder of 
record of medication as provided in RDC nº 4 of February 
10, 2009 (Brazil, 2009c).
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LEGISLATION
International Legislation
The regulations of radiopharmaceuticals initially 
established in the USA and Europe has gained attention 
of other producer countries of this therapeutic class, 
however, with a deficit of legislation. From the beginning, 
the USA and Europe have a solid legislation on 
radiopharmaceuticals.
USA
In  the  Un i t ed  S ta t e s ,  t he  Cons t i t u t iona l 
Amendment of 1938 first appeared with the intention 
of regulating this new therapeutic class. In 1944, the 
Department of Biological Products the Food and Drug 
Administration (FDA) has taken over the regulation of 
radiopharmaceuticals as biological component and, by 
presenting radioactive properties, for a long time they were 
also controlled by Atomic Energy Commission (AEC). In 
1954, the AEC was authorized to license the ownership, 
the use and transfer of materials considered by-products 
which included the radiopharmaceuticals. In 1963, the 
FDA allowed a temporary exemption for new radioactive 
and biological drugs regarding regulatory requirements 
for new investigational drugs, called Investigational New 
Drug (IND). In 1971, this exemption was annulled, passing 
to effective the regulatory requirements for Application of 
New Medicines, called Application New Drugs (NDA) 
for radiopharmaceuticals (Petry, 1989). In 1989, the FDA 
approved the radiopharmaceutical 82Rb - Rubidium 
chloride for the Evaluation of Myocardial Perfusion. In 
1997, the president of the United States has decreed that 
the FDA was component responsible for describing the 
procedures and Good Manufacturing Practices (GMP) 
for radiopharmaceuticals used in PET (Oliveira, 2008). 
The GMP for medicinal products in general are described 
in the Code of Federal Regulations (FRC), title 21, parts 
210 and 211 part 212 specifically, describes the GMP of 
radiopharmaceuticals PET because they are considered 
by the FDA a particular type of radiopharmaceuticals. In 
1998, it was added to the FRC 21, part 315, which refers 
to the regulation of radiopharmaceuticals for use in vivo 
diagnosis and monitoring.
Moreover, part 601 on License presents a sub-
part D (601.30 to 601.35) which specifically refers to 
radiopharmaceuticals (Araújo et al., 2008). The CFR 
title 10, chapter I, parts 1-199, is specifically dedicated 
to the Nuclear Regulatory Commission (NRC). While, 
many sections are applied to the practice of Nuclear 
Medicine, however the parties 20 (Standard is Protection 
against Radiation) and 35 (Medical Uses of Byproduct 
Material) are the most referenced when it comes to 
radiopharmaceuticals.
In 2000 three radiopharmaceuticals with diagnostic 
purposes were approved by the FDA, namely: the 18F - 
Sodium fluoride for bone scans, the 18F- Fluordesoxiglucose 
for use in oncology and assessment of myocardial viability 
and 13N-Nitrogen for evaluation of myocardial blood flow 
(Petry, 2004). Currently, the regulation and fiscalization 
of radiopharmaceuticals and medical equipment used in 
nuclear medicine are controlled by the FDA while the 
aspects related to radiation are controlled by the NRC. Other 
federal regulatory agencies such as Occupational Safety and 
Health Administration (OSHA), Environmental Protection 
Agency (EPA) and Department of Transportation (DOT) 
regulate the safety in industrial production, storage and of 
radiopharmaceuticals transportation.
Europe
The legal acts that culminated in regulation of 
radiopharmaceuticals in Europe were the directives 
published in 1986 and in 1989 (Oliveira, 2008). These 
directives were reviewed and updated over the years. In 
1991, the European Commission published the Directive 
91 /356/EEC that regulates in those GMP medicinal 
products for human use. Annex 3 which is part of the GMP 
guide is related to the production of radiopharmaceuticals, 
including topics such as installation, human resources, 
documentation, equipment,  quality control and 
distribution. This Annex applies to radiopharmaceuticals, 
PET radiopharmaceuticals, radioactive precursors for 
the production of radiopharmaceuticals and radionuclide 
generators (Araújo et al., 2008). The last update of this 
attachment was in March 2009. When there is some 
clinical research about radiopharmaceuticals, this will 
be considered as investigational product and must be 
produced in accordance with the principles of EudraLex 
(Rules and Government Regulations Medicines European 
Union), Volume 4 (Good Manufacturing Practice - GMP).
In the meantime, the European Association of 
Nuclear Medicine (EANM) has created a guide for the 
production of radiopharmaceuticals which is divided into 
product prepared from lyophilized reagents for tagging, 
PET radiopharmaceuticals and other locally produced 
(Araújo et al., 2008).
National Legislation
In Brazil, the term Radiopharmaceuticals appeared 
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for the first time in 1988 in the Brazilian Pharmacopoeia 
(Oliveira, 2008). In 1999 it was published the Law 
9.782/99 that says “Art 8: Delegate to the agency to 
regulate, control and supervise the products and services 
that involve risk to public health: IX - radioisotopes for 
in vivo diagnostic radiopharmaceuticals and radioactive 
products used in diagnosis and therapy “(Brazil, 1999). 
The most recent modification of the Brazilian Constitution 
of 1988 was due to the change in the wording of paragraph 
b, adding a paragraph c into the section XXIII of the main 
clause of Article 21 and the new text of section V of the 
chapeau of Article 177 (Brazil, 2006).
This term was used again only in 2006 when it 
created the Subcommittee on Radiopharmacy due to the 
initiative of the National Commission of Nuclear Energy 
(CNEN) and the Standing Committee of Revision of the 
Brazilian Pharmacopoeia (CPRFB). Thus, there was a 
rupture in the monopoly of production, marketing and use 
of radioisotopes of short half-life, for medical, agricultural 
and industrial in Brazil, designed by Constitutional 
Amendment 49 (Santos-Oliveira, Carneiro, Leão, 2008). 
Originate from the Proposed Constitutional Amendment 
199/03, which removes the Union’s the monopoly 
of manipulation of radioisotopes with short half-life, 
Constitutional Amendment 49 facilitated the creation of 
new nuclear medicine centers that offer the service of 
tomography to the population. The radioisotopes of short 
half-life are produced by institutes of CNEN (National 
Commission of Nuclear Energy) as the IEN (Institute of 
Nuclear Engineering) (Santos-Oliveira, Carneiro-Leão, 
2007; Santos-Oliveira, Carneiro-Leão, 2008).
Constitutional Amendment 49 brought a huge 
advance in Brazilian Radiopharmacy, because through 
it, it was found a new job market for pharmacists and 
many other professionals, whose market was previously 
restricted to institutions of CNEN.
Notwithstanding this fact imposed suddenly the 
Brazilian pharmacy a new paradigm, with many challenges 
and obstacles to overcome, starting by regulatory processes 
(Santos-Oliveira, Carneiro-Leão, 2007).
The subcommittee was responsible for updating the 
theoretical Pharmacopeia and elaboration of monographs 
where in 2007, through the Ordinance No. 42 of 
25/01/2007 it was established a Working Group composed 
of representatives of the Agency to develop regulations for 
the registration and inspection of these products, and on 
June 4, 2008 was published RDC 38 providing guidelines 
for the installation and operation of Nuclear Medicine 
Services “in vivo” (Brazil, 2008).
Recently,  ANVISA published two specific 
resolutions for radiopharmaceuticals - the RDC No. 
63 of 18 December, 2009 - establishing the minimum 
requirements for the manufacture and - RDC No. 64 
of December 18, 2009 - which describes the process of 
registration of these medicines (Brasil, 2009a,b).
From this resolution, all radiopharmaceutical for 
diagnostic or therapeutic use, being restricted to hospitals 
and clinics shall be registered in Brazil. Besides legislation 
ANVISA, CNEN published some standards and guidelines 
where divided into groups, e.g. Group 3: Radiological 
Protection (NE 3.01 (Brazil, 2005), NE 3:05 (Brazil, 2013), 
Group 6: Radioactive Facilities (NN 6:01 (Brazil, 1997) 
and Group 8: Radioactive Tailings NE 8.01 (Brazil, 2014).
RDC NO. 63 OF 18 DECEMBER 2009
Radiopharmaceuticals manufacturing
The requirements of the RDC No. 63, 18 December 
2009, intends to supplement the Resolution of Good 
Manufacturing Practice for Medicinal Products containing 
topics such as facilities, equipment, personnel, production, 
Documentation, Quality Assurance and Control. This 
Resolution provides the minimum requirements for the 
manufacturing of these products from production in 
industries and institutions to the preparation itself (Brazil, 
2009a).
Santos-Oliveira et al. (2008) wrote an article 
describing the manufacturing and sanitary aspects for the 
construction of a production line of radiopharmaceuticals. 
As RDC no. 63/2009 was in published only in 2009, 
by the year of publication of this Article, the authors based 
its content on the following documents: guidelines on 
standards of national and international quality referred 
to GMP for injectable medications; RDC 210/03 that is 
referred to the GMP applied to medicines in general and 
on standards of radiological protection and safety and 
security of workplace.
Thus the authors concluded that the development 
of industrial projects in this area based on these laws was 
impracticable for being radioactive medicinal product. For 
this reason too, the publication of the RDC no. 63/2009 
was of extreme importance in supporting and to supplying 
the information deficit regarding to the manufacture of 
radiopharmaceuticals (Brazil, 2009a).
RDC NO. 64 OF DECEMBER, 18th – 2009
Radiopharmaceuticals registration
RDC No. 64 of December 18, 2009 establishes 
all the steps to be followed for obtaining registration of 
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medications for both diagnostic and therapeutic use. The 
Chapter on Registry of such legislation is divided into three 
(3) sub-chapters: Chapter I: Initial Provisions, Chapter 
II: Imported Products and Chapter III: Registration 
Renewal. Chapter I has eight (8) sections such as: Section 
I: Background Measurements to the registry; Section 
II: Registration Documentation; Section III: Report on 
Clinical Efficacy and Safety; Section IV: Technical Report, 
Section V: Production Report and Quality Control, Section 
VI: Shelf Life; Section VII: Leaflet Text and Section VIII: 
Label Packaging Primary and Secondary. Furthermore, 
this resolution has two annexes, Annex I: Active Principles 
of Radiopharmaceuticals for Customary Use Annex II: 
Clinical Information Specific to the Radiopharmaceuticals 
Diagnostic (Brazil, 2009b).
The present Resolution establishes criteria for 
clinical studies of radiopharmaceuticals performed 
prior to their registration. In addition, manufacturers of 
radiopharmaceuticals should present pharmacovigilance 
reports (Brazil, 2009b).
The composition of the radiopharmaceutical agent, 
its half-life, as well as its properties, toxicology and 
physicochemical characteristics are required information 
mandatory for the register (Brazil, 2009b).
FINAL CONSIDERATIONS
The treatment with radiopharmaceuticals grows 
at a rate of 10% per year. In 2002, approximately 2 
million patients were treated at 278 hospitals and clinics 
throughout Brazil. In the United States, one-third of 
hospitalized patients receive some treatment with 
radiopharmaceutical (Regis, 2002). The benefits these 
patients enjoy are, mainly, regarding to early diagnosis of 
cancer, heart disease, neurological and much less invasive 
treatment and more effective in terms of tumors.
Radiopharmaceuticals are drugs of immediate 
effects. And with the objective of promoting the right of 
patients to have the life quality assured, every Brazilian 
citizen has his/her rights entitled to be respected by means 
of an efficient and responsible monitoring team set up.
In 2006, the monopoly of the manufacturer and 
marketing of radiopharmaceuticals was broken in Brazil 
and a prominent opportunity was perceived for new 
companies with innovative context for research and 
medications. When it comes to clinical history there is 
a lack of new studies, and there is a deficiency of new 
studies, researchers in this area and surveillances services 
too. In this sense, the publication of specific resolutions in 
the area is a major breakthrough for Brazil.
The resolutions are clear setting the term of 2 (two) 
years from the date of its publication for companies 
adaptation to the Technical Regulations (Brasil, 2009a,b). 
But, in December, 2011 was published RDC No. 66 which 
extended for over two years that any company producing 
radiopharmaceuticals technically adapt and follow the 
GMP of these drugs. Furthermore, this RDC also extended 
for three years the registration of the pertaining documents 
and maintenance and renewal of registration itself (Brazil, 
2011).
Brazil needs to engage in the arduous surveillance of 
new technologies such as radiopharmaceuticals. Thus, it 
can enable innovation in benefit of Brazilian health, where 
early diagnosis is just only one of several important tools 
within research that need to be available soon.
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